key: cord-0046370-ylmlw1sl
authors: Haagmans, Bart L.; Osterhaus, Albert D.M.E.
title: Severe acute respiratory syndrome (SARS) vaccines
date: 2020-06-22
journal: Vaccines
DOI: 10.1016/b978-1-4160-3611-1.50060-x
sha: 1a7b8a45654563e1663850412baacd693a9ae055
doc_id: 46370
cord_uid: ylmlw1sl

nan

Although the main clinical symptoms are those of severe respiratory illness, SARS-CoV actually also causes a gastrointestinal and urinary tract infection; SARS-CoV can be detected in the feces and urine of patients and electron microscopic studies of biopsies of the upper and lower intestinal mucosae of patients with SARS confi rmed the presence of the virus in these tissues 6 . Fecal transmission proved to be important in at least one major community outbreak in Hong Kong (Amoy Gardens), in which over 300 patients were infected within a few days.

Around 20-30% of individuals with SARS required management in intensive care units and the overall fatality rate reached approximately 10%. In typical cases, which were largely confi ned to adult and eldery individuals, SARS presented with acute respiratory distress syndrome (ARDS), characterized by the presence of diffuse alveolar damage (DAD) and multi organ dysfunction upon autopsy. 11 The pathological changes in lung alveoli most likely follow a common pathway characterized by an acute phase of protein-rich alveolar fl uid infl ux into the alveolar lumina as a consequence of the injury to the alveolar wall. Subsequently type-2 pneumocyte hyperplasia takes place to replace the loss of infected type-1 pneumocytes and to cover the denuded epithelial basement membrane, resulting in restoration of the normal alveolar architecture. Severe alveolar injury may lead to fi brosis with loss of alveolar function in more protracted cases.

Severe acute respiratory syndrome (SARS) emerged in Guandong Province, southern China, in November 2002. Although several infectious agents, including chlamydia, infl uenza A subtype H5N1 and human metapneumovirus were considered as a possible cause of SARS, three groups independently reported the isolation of a not previously discovered coronavirus (CoV) from clinical specimens of SARS patients. 1-3 Through electron microscopy, serology and reverse-transcription PCR with consensus-and random-primers and subsequent sequencing of the replicase gene, its identity could be revealed. This virus was consistently found in clinical specimens from patients with the disease and not in healthy controls. To conclusively establish a causal role for this CoV, cynomolgous macaques were inoculated with a SARS-CoV isolate. Because the disease in macaques caused by SARS-CoV infection was pathologically similar to that seen in human patients with SARS, and since the virus was successfully re-isolated from the nasal swabs (Fig. and lung lesions of these animals, and since a specifi c antibody response to the virus was shown in the infected animals, SARS-CoV proved to be the causative agent of this infectious disease. [4] [5] Background

The clinical symptoms of SARS-CoV infection are those of lower respiratory tract disease. Besides fever, malaise and peripheral T-cell lymphocytopenia, affected individuals have slightly decreased platelet counts, prolonged coagulation profi les and mildly elevated serum hepatic enzymes. [6] [7] Chest radiography reveals infi ltrates with subpleural consolidation or 'ground glass' changes compatible with viral pneumonitis.

The major sources of transmission in humans are droplets that deposit on the respiratory epithelium. Unlike the situation in several other respiratory viral infections, viral load of SARS-CoV in the upper respiratory tract increases progressively to peak at around day 10 after disease onset. 8 Therefore, virus transmission is lower in the fi rst days of illness, a fi nding supported by epidemiological observations. Overall, if superspreading events are not taken into account, transmissibility of SARS-CoV as indicated by the reproductive number (R 0 ) has been estimated to be relatively low (2-3). 9,10 genome also encodes two large poly-proteins with diverse enzymatic activities needed for effi cient replication and several accessory proteins with unknown function.

Three important features of the SARS pathogenesis may be relevant for intervention strategies. First, progressive age dependence in mortality and disease severity is observed in SARS patients. 14 In fact, none of the SARS-CoV infected children aged below 12-years in Hong Kong required intensive care or mechanical ventilation. 15 This is not totally explained by comorbid factors but similar age dependence in mortality is seen in patients with other (non-viral) causes of acute respiratory stress syndrome. 16 Secondly, virus transmission is low in the fi rst days of illness and peaks around day 10 after disease onset. 18 Finally, several studies revealed that high viral load in the nasopharyngeal aspirate was found to be an independent predictor of mortality. [17] [18] Therefore, vaccine strategies aimed at reducing the viral load may suffi ce to provide clinical benefi t.

Although seroconversion usually occurred in weeks 2 or 3 of illness, serodiagnosis represents the gold standard for confi rmation of a SARS diagnosis. Real-time PCR assays, however, usually detect SARS-CoV during the fi rst week in specimens of the lower respiratory tract (e.g., bronchoalveolar lavage, sputum, endotracheal aspirates), nasopharyngeal aspirate, throat swabs and/or serum. 19 Fecal samples may show very high viral loads toward the end of the fi rst week and second week of illness. More recently developed assays are able to detect SARS-CoV nucleocapsid protein in serum only few days after onset of disease. 20

The fi rst efforts to treat SARS patients were mainly based on the use of ribavirin and corticosteroids. Ribavirin, which targets IMP dehydrogenase, has been known a long time as a broadspectrum antiviral agent. However, current data do not support the use of ribavirin for SARS treatment; in vitro studies did not show signifi cant antiviral activity 21 and ribavirin enhanced the infectivity of SARS-CoV in mice. 22 On the other hand, a protective effect of interferon (IFN)-α has been obtained in a preliminary study during the SARS outbreak. 23 These results are in concordance with several studies that noted antiviral activity in vitro 21, 24 and animal studies showing that pegylated IFN-α effectively reduced SARS-CoV replication and excretion, viral antigen expression by type 1 pneumocytes and the pulmonary damage in cynomolgous macaques that were infected experimentally with SARS-CoV. 25 Because IFNs are used clinically to treat viral infections, these drugs could be considered for off label use in SARS prophylactic or early-postexposure treatment of SARS should it re-emerge.

Because many of the early SARS patients in Guandong had epidemiological links to the live-animal market trade, different animal species were tested for the presence of SARS like viruses. A SARS-like coronavirus, which had more than 99% homology with human SARS-CoV, was detected by RT-PCR in the nasal and fecal swabs of palm civets (Paguma larvata) and a raccoon dog (Nyctereutes procyonoides). 26 More recently, bats have been shown act as natural reservoirs for SARS-like CoVs. 27, 28 However, sequence comparison of the spike genes from bat SARS-like CoV and palm civet SARS-like CoV revealed only 64% genetic homology. Subsequent studies by Tang et al, have demonstrated that approximately 6% of bats sampled in China were positive for CoVs. 29 Interestingly, these CoVs are genetically diverse and many bat CoVs clustered with existing group 1 viruses, while others formed a separate lineage that included only viruses from bats (putative group 5). Other SARS-CoV like viruses clustered in a putative group 4 consisting of two subgroups, one of bat CoVs and another of SARS-CoVs from humans and other mammalian hosts. Although the direct progenitor of the SARS-CoV isolated from palm civets has not been determined, bats are the most likely reservoir of SARS-CoV that infected those animals. Subsequent major genetic variations in the spike gene of the viruses from civet cats seem to have been essential for the transition from animal to human transmission to human to human transmission that eventually caused the SARS outbreak of 2002-2003.

Overall, a wide range of animal species, including rodents (mice and hamsters), 30,31 carnivores (ferrets and cats) 32 and 

There is at present no evidence for the virus persisting in the human population. Possible options for the re-emergence of SARS include the re-emergence of the virus from an animal reservoir or the escape of the virus from laboratories, which already occurred on three occasions. The re-emergence of the virus from its animal reservoir remains possible, given that the virus is detectable in the feces and respiratory secretions of some animals. Indeed, SARS-CoV re-emerged in four patients in Guangdong in December 2003, although these SARS-like CoVs caused milder clinical disease. 36

In SARS patients that recover, high levels of neutralizing antibody responses are observed, suggesting that antibody responses play a role in determining the ultimate disease outcome of SARS-CoV-infected patients. 37 Although attempts have been made to test the effi cacy of serum preparations from seroconvalescent SARS patients in the acute phase of SARS, no conclusive evidence has been obtained regarding their effi cacy.

In mice, on the other hand, SARS-CoV infection is effi ciently controlled upon passive transfer of convalescent immunoglobulines. 30 The concept that antibodies protect against SARS has been further explored through the generation of human monoclonal antibodies against SARS-CoV. Prophylactic administration of a human monoclonal antibody reduced replication of SARS coronavirus in the lungs of infected ferrets by 3 logs, completely prevented the development of SARS coronavirusinduced macroscopic lung pathology, and abolished shedding of virus in pharyngeal secretions. 38 In subsequent studies several other monoclonal antibodies were evaluated for their effi cacy in mouse-and hamster-models. 39, 40 Active immunization

Less than a year after the fi rst SARS outbreak a range of candidate vaccines was developed and early 2006 some companies in China and the US initiated phase one trials and several other candidate SARS vaccines are at various stages of pre-clinical and clinical development. 

Inactivated SARS vaccines have been reported to elicit high titers of spike-specifi c neutralizing antibodies. Few studies, however, have addressed whether inactivated whole SARS-CoV virions confer protection from virus challenge. Mice that were immunized twice with a candidate SARS-CoV vaccine, produced through a two-step inactivation procedure involving sequential formaldehyde and U.V. inactivation, developed high antibody titres against the SARS-CoV spike protein and high levels of neutralizing antibodies. 41 Moreover, the vaccine conferred protective immunity as demonstrated by prevention of SARS-CoV replication in the respiratory tract of mice after intranasal challenge with SARS-CoV. Protection of mice was correlated to antibody titer against the SARS-CoV S protein and neutralizing antibody titer. Similar results have been obtained using a beta-propiolactone inactivated SARS-CoV vaccine in mice. 42 In addition, two Chinese groups have demonstrated protective effi cacy of inactivated SARS vaccines in rhesus monkeys. 43, 44 A soluble recombinant polypeptide containing the N-terminal segment of the spike glycoprotein may suffi ce to induce neutralizing antibodies and protective immunity in mice. 45 

A DNA vaccine encoding the spike glycoprotein of the SARS-CoV induces T cell and neutralizing antibody responses, as well as protective immunity, in a mouse model. 46 Moreover, antibody responses in mice vaccinated with an expression vector encoding a form of S that includes its transmembrane domain elicited neutralizing antibodies. Viral replication was reduced by more than six orders of magnitude in the lungs of mice vaccinated with these S plasmid DNA expression vectors, and protection was mediated by a humoral but not a T-cell-dependent immune mechanism. Subsequent studies using a prime-boost combination of DNA and whole killed SARS-CoV vaccines elicited higher antibody responses than DNA or whole killed virus vaccines alone. 47 Apart from this study, several other groups have analysed the immunogenicity of SARS DNA vaccines but none of these challenged the vaccinated animals with SARS-CoV.

Adenovirus-vector based vaccination strategies against SARS-CoV were employed early on after the SARS outbreak to demonstrate that vaccinated rhesus macaques developed virusneutralizing antibody responses against fragment S1 of spike and T-cell responses against the nucleocapsid. 48 More recently, See et al 49 demonstrated that vaccination of C57B1/6 mice with adenovirus type 5-expressing spike and nucleocapsid administered intranasally, but not intramuscularly, signifi cantly limited SARS-CoV replication in the lungs.

The highly attenuated modifi ed vaccinia virus Ankara (MVA) has been used to express the spike glycoprotein of SARS-CoV in vaccination experiments using mouse, ferret and rhesus monkey models. [50] [51] [52] Intranasal and intramuscular administration of MVA encoding the SARS-CoV spike protein led to the induction of a humoral immune response in BALB/c mice, as well as reduced viral titers in the respiratory tract. 45 Similary, protective responses were induced in rhesus monkeys. 46 However, in one study in ferrets, vaccination with MVA encoding the spike induced only moderate antibody responses and consequently did not protect against intranasal SARS-CoV infection but resulted in an infl ammatory response in the livers of the vaccinated ferrets. 52 Whether these aberrant responses resulted from immunopathological mechanisms, such as antibody dependent enhancement of infection or represented recall responses to viral antigen in the liver is not clear at the moment and deserves further investigation.

Recombinant bovine-human parainfl uenza virus type 3 vector (BHPIV3) is being developed as a live attenuated, intranasal pediatric vaccine against human parainfl uenza virus type 3. Immunization of African green monkeys with a single dose of BHPIV3 expressing SARS-CoV spike protein administered via the respiratory tract induced the production of SARS-CoV neutralizing antibodies. 53 A recombinant BHPIV3 expressing SARS-CoV structural protein (S, M and N) individually or in combination has been evaluated for immunogenicity and protective effi cacy in hamsters. 54 In the absence of spike, expression of M, N or E did not induce a detectable serum SARS-CoVneutralizing antibody response and no protection against SARS-CoV challenge in the respiratory tract, whereas the vectors expressing the S protein induced neutralizing antibody responses and protection.

Recombinant rabies virus expressing the S or the N protein of SARS-CoV induced a neutralizing antibody response in mice. 55 Similarly an attenuated vesicular stomatitis virus vector that encodes the SARS-CoV spike may be used to induce neutralizing antibody responses. 56 Mice vaccinated with this vesicular stomatitis virus developed SARS-CoV-neutralizing antibodies and were able to control a challenge with SARS-CoV performed at 1 month or 4 months after a single vaccination. In addition, by passive antibody transfer experiments, those authors demonstrated that the antibody response induced by the vaccine was suffi cient for controlling SARS-CoV infection.

Antibody and cellular responses

The importance of assessing immunogenicity of candidate SARS-CoV vaccines using VN assays is well acknowledged, but the variety of VN tests in use is a signifi cant problem since there is at this time no consensus on the most sensitive, specifi c and reproducible assay system. To compare data from each of the candidate vaccines requires international standardization of the immunological assays and the availability of an antibody standard used for the evaluation of these vaccines. To test cross reactivity of antibodies generated by vaccination, murine leukemia virus was used to generate infectious particles containing different S proteins. 57 The importance of cellmediated immunity in vaccine induced protection may be limited.

So far, work in animal models shows that neutralizing antibodies alone are effective for prevention and treatment of SARS. Thus, mice immunized with inactivated virus vaccines, liverecombinant vaccines expressing the SARS-CoV spike protein, using rabies virus, vesicular stomatitis virus, bovine parainfl uenza virus type 3, adenovirus or attenuated vaccinia virus MVA as a vector, as well as mice immunized with DNA vaccines expressing the spike gene, developed neutralizing antibodies to SARS-CoV and were protected against SARS-CoV challenge. Studies using monoclonal antibodies directed against different regions of the spike protein (S1 and S2) have demonstatrated potent neutralization of SARS-CoV in vitro. [58] [59] Conversely, peptides which are located in these regions were able to induce neutralizing antibodies. 45, 60, 61 More recent studies by He et al 62 have shown that the major neutralizing epitopes of SARS-CoV have been maintained during cross-species transmission, suggesting that receptor binding domain-based vaccines may induce broad protection against both human and animal SARS-CoV variants.

Although not all correlates of protection from SARS have been identifi ed in human SARS-CoV infections, neutralizing antibodies are present in convalescent human serum. However, the neutralizing antibody titer necessary to achieve protection in humans exposed to SARS-CoV is still unknown. Despite the fact that long-lived memory T cell responses against SARS-CoV nucleocapsid and spike protein have been demonstrated in recovered SARS patients their relevance in antiviral protection is not well understood. 63, 64 

Enhanced disease and mortality have been observed in kittens immunized against or infected with a type-I coronavirus, feline infectious peritonitis virus (FIPV), when subsequently exposed 56 Chapter 

to FIPV infection. 65 Macrophages are able to take up feline coronavirus-antibody complexes more effi ciently causing the virus to replicate to higher titers. Interestingly, one study also demonstrated that antibodies against human SARS-CoV isolates enhance entry of pseudo-typed viruses expressing the civet cat SARS-like CoV-spike protein into cells but not replication. 66 However, so far there is no evidence for enhanced replication following SARS-CoV challenge in previously immunized animals.

One other problem which may arise after vaccination with whole inactivated virus when absorbed with certain adjuvants such as alum, could relate to the induction of skewed Th2 recall responses similar to what has been observed in children vaccinated with inactivated respiratory syncytial and measles virus vaccines.

Although much effort has been focused on developing a SARS vaccine, the commercial viability of developing a vaccine for SARS-CoV will ultimately depend on whether the virus re-emerges in the near future. It is questionable whether possible future outbreaks will be major, but vaccines, antivirals or passive immunization would be relevant in the context of protecting high-risk individuals such as laboratory and health care workers. Alternatively, future vaccines may be generated from the full-length infectious cDNA clone of SARS-CoV 67 once viral virulence factors are understood and attenuated strains obtained through manipulation of the SARS-CoV genome.

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

Identifi cation of a novel coronavirus in patients with severe acute respiratory syndrome

Koch's postulates fulfi lled for SARS virus

Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome

Severe acute respiratory syndrome

Signifi cant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions

Transmission dynamics and control of severe acute respiratory syndrome

Lung pathology of fatal severe acute respiratory syndrome

Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

Prognostic factors for severe acute respiratory syndrome: a clinical analysis of 165 cases

SARS in newborns and children

Incidence and outcomes of acute lung injury

Viral loads in clinical specimens and SARS manifestations

Initial viral load and the outcomes of SARS

Detection of SARS coronavirus in patients with suspected SARS

Nucleocapsid protein as early diagnostic marker for SARS

Treatment of SARS with human interferons

Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study

Interferon-beta 1a and SARS coronavirus replication

Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques

Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China

Bats are natural reservoirs of SARS-like coronaviruses

Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats

Prevelance and genetic diversity of coronaviruses in bats from China

Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice

Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters

Virology: SARS virus infection of cats and ferrets

Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys

Macaque model for severe acute respiratory syndrome

Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans

Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong province

Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals

Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets

Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants

An effi cient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus

A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses

SARS vaccine protective in mice

Immunogenicity and protective effi cacy in monkeys of purifi ed inactivated Vero-cell SARS vaccine

Immunogenicity, safety, and protective effi cacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys

Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization

Effects of a SARS-associated coronavirus vaccine in monkeys

Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice

Recombinant modifi ed vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region

Immunization with modifi ed vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets

Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfl uenza virus expressing the SARS coronavirus spike protein for the prevention of SARS

Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity

A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies

Longterm protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine

Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus

Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents

Identifi cation of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies

Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein

Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients

Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARSrecovered patients

Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever

Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses

Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus